Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Sandoz at a glance
USD 208bn
Market size1
USD 9.1bn
FY 2022 net sales3,4
A European
champion
Growing at 8% 1,2 with
increasing share of Biosimilars
Strong pipeline
USD 1.9bn FY 2022
core EBITDA4
100+ markets
served
>400 Generics
25 Biosimilars
Broad coverage across Europe,
North America and International
And a global leader in
Generics and Biosimilars
Strong
management team
Supported by
>22,000 employees 5
4
1. Based on Company analysis using IQVIA Analytics Link MAT12-2022 data in LCUSD at gross price, excludes certain sizeable markets with no or limited Sandoz operations; 2. 2022-2031 CAGR for Biocomparable, Early Entry Generics and
Generics as defined by IQVIA and includes all ATC and NFC forms; 3. Net sales to third parties; 4. Based on unaudited carve-out financials extract. For additional information regarding the core results, which are non-IFRS measures, including a
reconciliation to the most directly comparable measures presented in accordance with IFRS, see "Appendix" starting on slide 31; 5. Approximate number of FTEs at spin-off.
Management Presentation
SANDOZView entire presentation